Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neuro-oncology

Standard of Care Treatment for Astrocytoma

At a Glance

Astrocytoma treatment is personalized based on your tumor's grade and genetic markers like IDH and MGMT. The standard of care begins with maximal safe surgery, followed by a customized combination of radiation, chemotherapy, or targeted daily pills like vorasidenib for lower-grade tumors.

The goal of astrocytoma treatment is to control the tumor for as long as possible while protecting your quality of life. Because every tumor is biologically unique, your treatment plan is built like a puzzle, using your tumor’s grade, IDH status, and MGMT status as the primary pieces [1][2].

Step 1: Surgery (The Foundation)

The first and most critical step is almost always surgery. The standard approach is a maximal safe resection—the goal is to remove as much of the tumor as possible without damaging essential brain areas that control movement, speech, or vision [3][4].

In some cases, surgeons may perform a supratotal resection, removing a small margin of tissue around the visible tumor to further delay recurrence [5][6]. They only do this when advanced mapping techniques, like functional MRIs and awake mapping, confirm that removing this tissue is safe and will not impact your cognitive or physical abilities.

Step 2: Adjuvant Therapy (The Follow-up)

After surgery, your care team decides on “adjuvant” (additional) therapy based on your specific risk factors.

  • Grade 2 (Lower Risk): If you are young and the surgeon removed all visible tumor, your team might suggest “watchful waiting” with frequent MRI scans [1][3].
  • Grade 2 (Higher Risk) or Grade 3: These often require a combination of Radiation Therapy (targeted X-ray beams) and Chemotherapy, typically temozolomide (TMZ) or a combination regimen known as PCV (procarbazine, lomustine, and vincristine) [7][8].
  • Grade 4: Because these are more aggressive—often defined by the presence of a CDKN2A/B deletion—they are treated more intensively, usually following a protocol of radiation and daily chemotherapy [9][10].

The Role of MGMT Status

Your MGMT promoter methylation status acts as a “predictor” for how well chemotherapy might work.

  • Methylated: The tumor’s ability to repair itself is weakened, making it more likely that temozolomide will be highly effective [11][12].
  • Unmethylated: While it suggests the tumor might resist some forms of chemotherapy, chemo is still usually administered because IDH-mutant tumors often still benefit from it. Your team will carefully monitor your response [13][14].

Targeted Therapy: Vorasidenib

A significant recent advancement is a drug called vorasidenib. It is an FDA-approved daily pill for patients 12 years and older with Grade 2 IDH-mutant tumors that could not be fully removed by surgery or have recurred [15][16].

  • What does it do?: Research has shown it can significantly delay the time until the tumor starts growing again, potentially allowing patients to delay more intensive treatments like radiation for years [17][18].
  • Safety Warning: While it can significantly delay the need for harsher treatments, it carries a known risk of hepatotoxicity (elevated liver enzymes). Patients taking vorasidenib must commit to frequent blood tests to closely monitor their liver health.

Note on Higher Grades: For patients with Grade 3 or Grade 4 tumors, vorasidenib is not currently indicated. For these higher grades, new targeted therapies are primarily accessed through clinical trials, making it crucial to receive care at a major research center.

Treatment Logic Summary

Your treatment path generally follows this logic:

If your tumor is… And your status is… The typical approach is…
Grade 2 Low Risk Surgery followed by observation [1].
Grade 2 Residual tumor Consider Vorasidenib [15].
Grade 3 IDH-mutant Surgery + Radiation + Chemotherapy (TMZ or PCV) [7].
Grade 4 CDKN2A/B deleted Intensive Surgery + Radiation + Chemotherapy [9].

Note: This table is a general guide; your team will personalize these options based on your overall health and goals. [2]

Common questions in this guide

What is a maximal safe resection for astrocytoma?
A maximal safe resection is a surgical procedure where the goal is to remove as much of the brain tumor as possible. The surgeon carefully avoids damaging essential brain areas that control vital functions like movement, speech, and vision.
How does my MGMT status affect my chemotherapy options?
Your MGMT promoter methylation status acts as a predictor for how well chemotherapy will work. If your tumor is methylated, it has a weaker ability to repair itself, making the chemotherapy drug temozolomide highly effective.
What is vorasidenib and who can take it?
Vorasidenib is an FDA-approved targeted therapy pill used for patients 12 and older with Grade 2 IDH-mutant astrocytomas that have recurred or could not be fully removed. It can significantly delay the tumor's growth and postpone the need for harsher treatments like radiation.
Why do I need frequent blood tests if I take vorasidenib?
Vorasidenib carries a known risk of causing elevated liver enzymes, a condition known as hepatotoxicity. Frequent blood tests are required to closely monitor your liver health and ensure the medication is not causing damage while you take it.
How is a Grade 4 astrocytoma treated differently than lower grades?
Grade 4 astrocytomas are more aggressive and often defined by specific genetic features like a CDKN2A/B deletion. Because of this, they require a more intensive treatment protocol that typically combines surgery with both radiation and daily chemotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my surgery considered a 'gross total resection' or a 'maximal safe resection,' and is there any residual tumor left?
  2. 2.Based on my tumor's grade and MGMT status, is radiation, chemotherapy, or both recommended for me right now?
  3. 3.If I have a Grade 2 tumor, am I a candidate for vorasidenib to delay more aggressive treatments?
  4. 4.How does my MGMT methylation status change your confidence in using temozolomide versus PCV?
  5. 5.If my tumor is Grade 4 due to a CDKN2A/B deletion, how does that change the intensity of my treatment compared to a Grade 2 or 3 tumor?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

    van den Bent MJ, French PJ, Brat D, et al.

    Neuro-oncology 2024; (26(10)):1805-1822 doi:10.1093/neuonc/noae107.

    PMID: 38912846
  2. 2

    A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.

    Tran S, Thomas A, Aliouat I, et al.

    Neuropathology and applied neurobiology 2023; (49(4)):e12928 doi:10.1111/nan.12928.

    PMID: 37503540
  3. 3

    Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.

    Patel SH, Bansal AG, Young EB, et al.

    AJNR. American journal of neuroradiology 2019; (40(7)):1149-1155 doi:10.3174/ajnr.A6102.

    PMID: 31248860
  4. 4

    The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma.

    Aiudi D, Iacoangeli A, Dobran M, et al.

    Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030849.

    PMID: 38337543
  5. 5

    Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas.

    Rossi M, Gay L, Ambrogi F, et al.

    Neuro-oncology 2021; (23(5)):812-826 doi:10.1093/neuonc/noaa225.

    PMID: 33049063
  6. 6

    Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.

    Falcão L, Cerqueira GA, Gonçalves JPF, et al.

    Neurosurgical review 2025; (48(1)):281.

    PMID: 40032671
  7. 7

    Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.

    Rautajoki KJ, Jaatinen S, Hartewig A, et al.

    Acta neuropathologica communications 2023; (11(1)):176 doi:10.1186/s40478-023-01669-9.

    PMID: 37932833
  8. 8

    The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.

    Kinslow CJ, Roy S, Iwamoto FM, et al.

    Neuro-oncology 2024; (26(10)):1839-1849 doi:10.1093/neuonc/noae102.

    PMID: 38943513
  9. 9

    Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.

    Fortin Ensign SP, Jenkins RB, Giannini C, et al.

    Neuro-oncology 2023; (25(1)):28-36 doi:10.1093/neuonc/noac205.

    PMID: 35973817
  10. 10

    A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.

    Wetzel EA, Nohman AI, Hsieh AL, et al.

    Journal of neuro-oncology 2025; (171(2)):373-381 doi:10.1007/s11060-024-04852-7.

    PMID: 39432026
  11. 11

    Prognostic and Predictive Biomarkers in Gliomas.

    Śledzińska P, Bebyn MG, Furtak J, et al.

    International journal of molecular sciences 2021; (22(19)) doi:10.3390/ijms221910373.

    PMID: 34638714
  12. 12

    Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.

    Li H, Wu Y, Chen Y, et al.

    Acta neuropathologica communications 2025; (13(1)):126 doi:10.1186/s40478-025-02046-4.

    PMID: 40468460
  13. 13

    Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

    Lam K, Eldred BSC, Kevan B, et al.

    Neuro-oncology advances 2022; (4(1)):vdac030 doi:10.1093/noajnl/vdac030.

    PMID: 35386566
  14. 14

    Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.

    Dahlrot RH, Larsen P, Boldt HB, et al.

    Journal of neuropathology and experimental neurology 2019; (78(7)):633-640 doi:10.1093/jnen/nlz032.

    PMID: 31058280
  15. 15

    Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

    Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al.

    The New England journal of medicine 2023; (389(7)):589-601 doi:10.1056/NEJMoa2304194.

    PMID: 37272516
  16. 16

    Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.

    Rudà R, Bruno F, Pellerino A, et al.

    Expert opinion on pharmacotherapy 2025; (26(10)):1163-1175 doi:10.1080/14656566.2025.2516617.

    PMID: 40479721
  17. 17

    The Role of Mutant IDH Inhibitors in the Treatment of Glioma.

    Nakhate V, Lasica AB, Wen PY

    Current neurology and neuroscience reports 2024; (24(12)):631-643 doi:10.1007/s11910-024-01378-3.

    PMID: 39302605
  18. 18

    Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

    Cloughesy TF, van den Bent MJ, Touat M, et al.

    The Lancet. Oncology 2025; (26(12)):1665-1675 doi:10.1016/S1470-2045(25)00472-3.

    PMID: 41175888

This page provides educational information about standard astrocytoma treatments. Always consult your neuro-oncologist or neurosurgeon to determine the best treatment plan for your specific tumor grade and genetics.

Get notified when new evidence is published on Astrocytoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.